Кое что из Монголии

ЦитатаWe sequenced 97 nasal samples from Covid-19 patients with breakthrough infections  after vaccination (Supplementary Table 1), and tested plasma from 100 healthy subjects   for antibodies to SARS-CoV-2 (surface glycoprotein, S and nucleocapsid  
phosphoprotein, NCP), and NAb after Covishield/AstraZeneca, Sputnik V, Sinopharm,  or Pfizer/BioNTech vaccination (Table 1).  
Full-length SARS-CoV-2 sequences were obtained from 92 samples. Eighty-seven of  92 (94.6%) were Alpha variant. Five of 92 (5.4%) were Delta variant. Of 87 Alpha  variant breakthrough infections, 54 (62.1 %) were from Sinopharm, 7 (8.0%) from Sputnik V, 23 (26.4%) from Covishield/AZN, and 3 (3.4%) from Pfizer/BioNTech  vaccinees. Of 5 breakthrough Delta variant infections, 1 (20%) was from Sinopharm, 3   (60%) were from Covishield/AZN, and 1 (20%) was from Pfizer/BioNTech vaccinees  
(Supplementary Table 1).  
More subjects had spike ELISA reactivity after Pfizer/BioNTech (91.6%), and  Covishield/AstraZeneca (70.8%), than Sputnik V (29.2%) or Sinopharm (12.5%).  Nucleoprotein reactivity was present in 12.5% of Sinopharm vaccinees. One  Covishield/AstraZeneca vaccinee was NP positive, presumably because of infection.  Only Sinopharm contains NP. Three of four subjects (75%) who received two  Sinopharm doses followed by one Pfizer/BioNTech dose were spike-positive (Table 1)  
(Supplemental Figure 1). More subjects had NAb to WA strain after Pfizer/BioNTech   (79.7%), and Covishield/AstraZeneca (50.0%), than after Sputnik V (25.0%) or   Sinopharm (20.8%). Neutralizing antibodies to Delta variants were present in fewer  
 subjects after Pfizer/BioNTech (29.2%), Sputnik V (8.33%), and Sinopharm (12.5%).   NAb to Delta variants were detected in nine subjects after Covishield/AZN (37.50%);  however, 3/9 were NCP ELISA-positive indicating previous SARS-CoV-2 exposure.   Eliminating these three subjects would decrease the percentage with NAb to Delta to  25%. Three of four vaccinees who received a single dose of Pfizer/BioNTech after two  doses of Sinopharm had NAb to WA; one had NAb to Delta.

ЦитатаNeutralizing antibodies to Delta variants were present in fewer  

 subjects after Pfizer/BioNTech (29.2%), Sputnik V (8.33%), and Sinopharm (12.5%).